Home » Stocks » GRCL

Gracell Biotechnologies, Inc. (GRCL)

Stock Price: $12.93 USD 0.24 (1.89%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Pre-market: $12.90 -0.03 (-0.23%) Apr 23, 4:00 AM
Market Cap 847.73M
Revenue (ttm) n/a
Net Income (ttm) -41.99M
Shares Out 65.56M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $12.93
Previous Close $12.69
Change ($) 0.24
Change (%) 1.89%
Day's Open 12.91
Day's Range 12.52 - 13.39
Day's Volume 22,039
52-Week Range 12.02 - 33.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effic...

1 week ago - PRNewsWire

SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering ...

2 weeks ago - GlobeNewsWire

SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and ...

3 weeks ago - PRNewsWire

SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effic...

3 weeks ago - PRNewsWire

SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and dev...

1 month ago - GlobeNewsWire

Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMA/CD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enabled ...

1 month ago - GlobeNewsWire

SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effica...

3 months ago - PRNewsWire

SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and aff...

3 months ago - PRNewsWire

SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effica...

3 months ago - PRNewsWire

China's Gracell Biotechnologies Lists on Nasdaq

YouTube video

Jan.10 -- William Cao, founder and chief executive officer of Gracell Biotechnologies, discusses the Shanghai-based company's initial public offering in the U.S. and its growth strategy. Gracell is deve...

3 months ago - Bloomberg Markets and Finance

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: ARGX, EYPT, GILD, INO, LLY, PRTK, ZLAB
3 months ago - Seeking Alpha

SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing...

3 months ago - PRNewsWire

Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, announced terms for its US IPO on Monday. The Suzhou, China-based company plans to raise $150 million by of...

3 months ago - NASDAQ

Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

4 months ago - NASDAQ

Gracell Biotechnologies, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and...

4 months ago - PRNewswire

About GRCL

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms—FasTCAR and TruUCAR. Chimeric antigen receptor T cells, or CAR-T cells, can be classified as either autologous or allogeneic. Autologous CAR-T cells are derived from the T cells of the cancer patien... [Read more...]

Industry
Biotechnology
IPO Date
Jan 8, 2021
CEO
William Wei Cao, Ph.D. B.M.
Employees
160
Stock Exchange
NASDAQ
Ticker Symbol
GRCL
Full Company Profile

Financial Performance

Financial numbers in millions CNY.
Financial Statements